The use of resistin as a biomarker to identify patients is a proactive strategy because the results can help clinicians monitor psoriasis patients for significant increases in viral co-infections, such as HSV or HIV, while offering a more specific treatment for patients at high risk of suffering from concomitant viral infections. This evidence concerns the gene RETN and psoriasis.